What is the recommended dose of a 0.125 mg Methergine (methylergometrine) tablet for treating uterine atony?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 11, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Methergine (Methylergonovine) Dosing for Uterine Atony

For uterine atony refractory to oxytocin, methylergonovine 0.2 mg intramuscular is the standard dose, not 0.125 mg. 1, 2

Standard Dosing Protocol

The 0.125 mg tablet formulation you mentioned is not the recommended dose for acute uterine atony management. The evidence-based dosing is:

  • Methylergonovine 0.2 mg intramuscular is the established second-line uterotonic dose for oxytocin-refractory uterine atony 1, 2
  • This 0.2 mg dose demonstrates equivalent efficacy to carboprost tromethamine (another second-line agent), with mean uterine tone scores of 7.3±1.7 at 10 minutes post-administration 2
  • The 0.2 mg dose can be repeated if needed, though specific repeat-dosing intervals are not standardized in the literature 1

Clinical Context

Methylergonovine works as a second-line agent when oxytocin fails to restore adequate uterine tone:

  • Oxytocin remains the first-line agent for both prevention and treatment of uterine atony 3, 1
  • For cesarean delivery, oxytocin bolus doses of 1 IU (elective) to 3 IU (intrapartum) are typically sufficient 3
  • When uterine atony persists despite oxytocin, second-line agents like methylergonovine should be administered early rather than delayed 3
  • Approximately 30% of patients receiving methylergonovine 0.2 mg may require additional second-line uterotonics 2

Route of Administration

  • Intramuscular injection is the standard route for acute uterine atony management 1, 2, 4
  • Oral tablet formulations exist but are not appropriate for acute hemorrhage scenarios requiring immediate uterotonic effect 1

Critical Contraindications

Before administering methylergonovine, verify the patient does not have:

  • Hypertension or preeclampsia (methylergonovine causes vasoconstriction and can precipitate hypertensive crisis) 1
  • Coronary artery disease or peripheral vascular disease 1
  • Sepsis 1

Alternative Second-Line Agents

If methylergonovine is contraindicated:

  • Carboprost tromethamine 250 mcg intramuscular demonstrates equivalent efficacy (mean 10-minute uterine tone score 7.6±2.1) 2
  • Carboprost is contraindicated in asthma but may be used in hypertensive patients 1
  • Misoprostol 800-1000 mcg (sublingual or rectal) is less effective than methylergonovine or carboprost but useful in resource-limited settings 3, 1, 4

Common Pitfall to Avoid

Do not use the 0.125 mg dose for acute uterine atony—this underdoses the patient and delays effective hemorrhage control. The 0.2 mg intramuscular dose is the evidence-based standard that has been validated in randomized trials. 1, 2

Related Questions

What are the guidelines for managing postpartum hemorrhage (PPH) due to delivery bleeding?
What is the dosage of Oxytocin (Pitocin) after birth?
What is the best next step in managing a postpartum woman with severe vaginal bleeding, uterine atony, and tachycardia, unresponsive to uterine massage and high-dose oxytocin?
What is a potential cause of uterine atony?
What are examples of uterotonic agents?
What is the first‑line vasopressor and its recommended dosing for a pregnant patient requiring pharmacologic support for hypotension or shock, and what are acceptable alternatives?
What are the changes in the diagnosis of hallucinogen‑related disorders across the Diagnostic and Statistical Manual of Mental Disorders (DSM) versions III, III‑TR (Text Revision), IV, V, and V‑TR (Text Revision), and the International Classification of Diseases (ICD) versions X and XI?
Is N‑acetylcysteine appropriate for an adult with a productive (wet) cough such as acute bronchitis, and what are the recommended dosage, duration, and safety considerations?
What are the strengths and weaknesses of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM‑5‑TR) and the International Classification of Diseases, Eleventh Revision (ICD‑11) in diagnosing hallucinogen‑related disorders?
What is the recommended dose and dosing interval of oral methylergometrine 0.125 mg tablet for postpartum uterine tone maintenance?
Are there any safety concerns when combining clopidogrel with omega‑3 fatty acid (fish‑oil) supplements?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.